Prognostic and predictive markers in canine tumours: rationale and relevance. A review
- PMID: 16022341
- DOI: 10.1080/01652176.2005.9695186
Prognostic and predictive markers in canine tumours: rationale and relevance. A review
Abstract
Cancer is one of the most common causes of death in dogs. The availability of multiple treatment modalities and novel therapeutic targets make the correct diagnosis, prognostic stratification, and the identification of treatment effect predictive factors an issue of major debate in cancer management. Selection of high and low risk patients and the type of systemic or local treatment is important in cancer management. The search for better prognostic markers and predictive factors is now focused on the molecular mechanisms which underlie tumour behaviour, such as altered cell cycle progression, proliferation, apoptosis, and angiogenesis. The ultimate goal is to identify reliable markers that can accurately diagnose and stage a tumour and predict tumour's clinical behaviour, prognosis and response to therapy. In this review, the current state of prognostication in canine tumours and promising new molecular markers are discussed. The markers are allocated to four groups according to their function: (i) proliferation markers, (ii) apoptosis, (iii) extracellular matrix and cell adhesion molecules, (iv) angiogenesis and (v) cell cycle regulators. Clinicopathological factors and histopathological grading remain the most practical parameters in decision-making. Although experimental research has shown that molecular markers have a good potential to be used as diagnostic, prognostic or predictive markers in canine tumours, insufficient evidence exists on their efficacy for routine use in veterinary oncology.
Similar articles
-
Prognostic relevance of molecular markers of oral cancer--a review.Int J Oral Maxillofac Surg. 2003 Jun;32(3):233-45. doi: 10.1054/ijom.2002.0383. Int J Oral Maxillofac Surg. 2003. PMID: 12767868 Review.
-
Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease.Sci Rep. 2017 May 23;7(1):2301. doi: 10.1038/s41598-017-02607-1. Sci Rep. 2017. PMID: 28536479 Free PMC article.
-
A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.Vet Comp Oncol. 2018 Dec;16(4):467-477. doi: 10.1111/vco.12402. Epub 2018 May 24. Vet Comp Oncol. 2018. PMID: 29797763
-
Blood biomarkers for canine cancer, from human to veterinary oncology.Vet Comp Oncol. 2022 Dec;20(4):767-777. doi: 10.1111/vco.12848. Epub 2022 Jul 20. Vet Comp Oncol. 2022. PMID: 35815441 Free PMC article. Review.
-
Canine paediatric oncology: retrospective assessment of 9522 tumours in dogs up to 12 months (1993-2008).Vet Comp Oncol. 2010 Dec;8(4):283-92. doi: 10.1111/j.1476-5829.2010.00226.x. Vet Comp Oncol. 2010. PMID: 21062410
Cited by
-
Canine cancer immunotherapy studies: linking mouse and human.J Immunother Cancer. 2016 Dec 20;4:97. doi: 10.1186/s40425-016-0200-7. eCollection 2016. J Immunother Cancer. 2016. PMID: 28031824 Free PMC article. Review.
-
Onco-epidemiology of domestic animals and targeted therapeutic attempts: perspectives on human oncology.J Cancer Res Clin Oncol. 2014 Nov;140(11):1807-14. doi: 10.1007/s00432-014-1664-9. Epub 2014 May 11. J Cancer Res Clin Oncol. 2014. PMID: 24816783 Free PMC article. Review.
-
Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors.J Oncol. 2019 May 2;2019:6201764. doi: 10.1155/2019/6201764. eCollection 2019. J Oncol. 2019. PMID: 31186637 Free PMC article.
-
The High Expression of Legumain in Canine Neoplasms: A Retrospective Analysis of 100 Cases.Animals (Basel). 2022 Feb 17;12(4):504. doi: 10.3390/ani12040504. Animals (Basel). 2022. PMID: 35203212 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources